Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||TP53 R248W|
|Gene Variant Detail|
|Relevant Treatment Approaches||p53 Activator p53 Gene Therapy|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 R248W||lung non-small cell carcinoma||sensitive||p53 Activator||APR-246 + Cisplatin||Preclinical||Actionable||In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).||26086967|
|TP53 R248W||colon carcinoma||predicted - sensitive||AZ32 + Radiotherapy||Preclinical - Cell culture||Actionable||In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in colon carcinoma cells harboring TP53 R248W compared to radiotherapy alone in culture, resulting in increased mitotic catastrophe; however, wild-type TP53 cells were more sensitive to the treatment combination than TP53 R248W mutant cells (PMID: 29769307).||29769307|